Euro Pacific Asset Management LLC Boosts Holdings in Novo Nordisk A/S $NVO

Euro Pacific Asset Management LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 24.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 346,077 shares of the company’s stock after acquiring an additional 67,261 shares during the period. Novo Nordisk A/S makes up approximately 0.1% of Euro Pacific Asset Management LLC’s holdings, making the stock its 17th biggest holding. Euro Pacific Asset Management LLC’s holdings in Novo Nordisk A/S were worth $17,608,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Capital International Investors lifted its holdings in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares during the last quarter. Folketrygdfondet raised its position in shares of Novo Nordisk A/S by 1.2% in the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after purchasing an additional 117,370 shares during the last quarter. State Street Corp boosted its stake in Novo Nordisk A/S by 1.0% in the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock worth $340,125,000 after purchasing an additional 59,153 shares in the last quarter. Finally, Boston Partners acquired a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $310,199,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 2.1%

Shares of Novo Nordisk A/S stock opened at $35.28 on Tuesday. The stock has a market cap of $157.53 billion, a PE ratio of 10.17, a price-to-earnings-growth ratio of 8.52 and a beta of 0.74. The firm has a fifty day moving average price of $45.38 and a 200 day moving average price of $50.29. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Company-initiated share repurchase programme — Novo Nordisk confirmed its ongoing buyback (part of up to DKK 15 billion over 12 months, programme started 4 Feb). Buybacks reduce float and are direct shareholder-return support. Share repurchase programme
• Positive Sentiment: High-profile endorsement/coverage — Jim Cramer named NVO among weight‑loss/GLP‑1 picks and media pieces highlight this, which can spur retail interest and short‑term buying. Jim Cramer buyer coverage
• Positive Sentiment: Analyst/idea pieces argue the stock remains an attractive opportunity — at least one Seeking Alpha write‑up reiterates a longer‑term bullish case, which may attract value/long investors amid the pullback. Seeking Alpha analysis
• Neutral Sentiment: Mars CEO named a board observer — Poul Weihrauch will be a board observer at Novo Nordisk; notable for industry ties and governance visibility but unlikely to be an immediate earnings driver. Mars CEO board observer
• Neutral Sentiment: Spike in investor searches/attention — Zacks/Yahoo note heavy search activity on NVO, reflecting elevated retail interest but not necessarily new fundamentals. Investor search activity
• Neutral Sentiment: Sector and market flow context — broader pharma/European ADR coverage (Pfizer/GSK sector pieces, European ADR trading) may be influencing relative flows into/away from large-cap pharma names like NVO. Pharma sector coverage
• Negative Sentiment: Weak recent share performance / valuation concerns — analyst write‑ups highlight negative returns over recent periods and fading momentum, raising questions about near‑term catalysts and putting downward pressure on the stock. Valuation and performance assessment

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NVO shares. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Four analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.